Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 11, 2014, Pages 995-1002

  Nascimento, M M ^a,b,c   Hayashi, S Y ^a,d   Riella, M C ^c,e   Lindholm, B ^a  

^a Divisions of Baxter Novum and Renal Medicine   (Sweden)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^e PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Atherosclerosis; Chronic kidney disease; Inflammation; Mortality; Osteoprotegerin

Indexed keywords

C REACTIVE PROTEIN; FETUIN; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 6; OSTEOPROTEGERIN; PARATHYROID HORMONE; PENTRAXIN 3; PHOSPHATE; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MORTALITY; SURVIVAL RATE; TISSUE DOPPLER IMAGING; TREATMENT OUTCOME; ADOLESCENT; BLOOD; BRAZIL; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; COMPLICATION; DOPPLER ECHOCARDIOGRAPHY; EPIDEMIOLOGY; HEART FUNCTION TEST; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; RISK; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOMARKERS; BRAZIL; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CAUSE OF DEATH; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FIBROBLAST GROWTH FACTORS; HEART FUNCTION TESTS; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPROTEGERIN; RENAL INSUFFICIENCY, CHRONIC; RISK; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84923344053     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20144007     Document Type: Article

References (23)

1. Mesquita M, Demulder A, Wolff F, Melot C, Damry N, Dratwa M, et al. Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease. Transplant Proc 2010; 42: 3444-3449, doi: 10.1016/j.transproceed.2010.09.129.
2. Mesquita M, Demulder A, Damry N, Melot C, Wittersheim E, Willems D, et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med 2009; 47: 339-346, doi: 10.1515/CCLM.2009.075.
3. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006; 17: 262-270, doi: 10.1681/ASN.2005030260.
4. Nakashima A, Carrero JJ, Qureshi AR, Hirai T, Takasugi N, Ueno T, et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int 2011; 22: 1695-1701, doi: 10.1007/s00198-010-1377-0.
5. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007; 49: 1392-1398, doi: 10.1161/HYPERTENSIONAHA.107.087742.
6. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008; 51: 627-633, doi: 10.1016/j.jacc.2007.09.058.
7. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21: 93-111, doi: 10.1016/j.echo.2007.11.011.
8. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463, doi: 10.1016/j.echo.2005.10.005.
9. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echo-cardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167-184, doi: 10.1067/mje.2002.120202.
10. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007; 99: 513-518, doi: 10.1016/j.amjcard.2006.08.064.
11. Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009; 24: 3157-3162, doi: 10.1093/ndt/gfp253.
12. Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimburger O, et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 2009; 22: 774-782.
13. Anand DV, Lim E, Darko D, Bassett P, Hopkins D, Lipkin D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 2007; 50: 2218-2225, doi: 10.1016/j.jacc.2007.08.032.
14. Beaussier H, Masson I, Collin C, Bozec E, Laloux B, Calvet D, et al. Carotid plaque, arterial stiffness gradient, and remodeling in hypertension. Hypertension 2008; 52: 729-736, doi: 10.1161/HYPERTENSIONAHA.108.115972.
15. Pateinakis P, Papagianni A, Douma S, Efstratiadis G, Memmos D. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol 2013; 14: 122, doi: 10.1186/1471-2369-14-122.
16. Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, et al. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol 2012; 7: 965-973, doi: 10.2215/CJN.11191111.
17. Winther S, Christensen JH, Flyvbjerg A, Schmidt EB, Jorgensen KA, Skou-Jorgensen H, et al. Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clin Nephrol 2013; 80: 161-167, doi: 10.5414/CN107803.
18. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-1028, doi: 10.1210/jc.2002-020775.
19. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319, doi: 10.1016/S0092-8674(00)80209-3.
20. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study. J Thromb Haemost 2011; 9: 638-644, doi: 10.1111/j.1538-7836.2011.04222.x.
21. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Bohm M, Mach F, et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011; 4: 145-152, doi: 10.1161/CIRCHEARTFAILURE.110.957332.
22. Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, et al. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010; 33: 2561-2566, doi: 10.2337/dc10-0858.
23. Shaker OG, El-Shehaby A, Nabih M. Possible role of osteoprotegerin and tumor necrosis factor-related apopto-sis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology 2010; 61: 756-762, doi: 10.1177/0003319710370961.